Influenza vaccine live(MedImmune LLC)

Zest Clinic announced the introduction of FluMist, a needle-free intranasal influenza vaccine, as part of its preventive health services. Getting vaccinated is the simplest way to protect yourself and your loved ones. With needle-free options like FluMist, staying protected has never been easier.” — Dr Sankeerth Reddy SINGAPORE, SINGAPORE, January 6, 2026 / EINPresswire.com / -- Zest Clinic, a medical aesthetics and wellness clinic in Marine Parade, announced the introduction of FluMist, a needle-free intranasal influenza vaccine, as part of its preventive health services. Known to many patients as a longevity clinic and Botox clinic , Zest Clinic is broadening its focus on health and longevity by adding more vaccination options alongside its wellness services. The new offering sits within the clinic’s existing wellness portfolio. Patients who attend for skin, hair or anti-ageing concerns – including treatments such as collagen booster injection – will now be able to discuss influenza prevention during the same visit, where appropriate. By bringing aesthetic medicine and preventive healthcare together, the clinic aims to make conversations about long-term health more fun and engaging. Zest Clinic’s doctors also provide injectable treatments for facial volume and contouring, such as sculptra injections and are accustomed to counselling patients about risk, benefit and suitability. The same consultation-led approach will be used when discussing whether FluMist or a traditional injectable flu vaccine is the better option for an individual patient. For those who avoid the annual vaccination due to fear of needles or pain concerns, this is a must have. With the influenza season at its peak, this offers a painless approach to protect yourself and your loved ones from Influenza viruses. FluMist is an intranasal, needle-free influenza vaccine that has long been approved by the United States Food and Drug Administration and has recently received approval for use in Singapore. Delivered as a nasal spray rather than an injection, it offers an alternative for individuals who wish to protect themselves against seasonal flu but are hesitant about needles. In Singapore, it is currently approved for administration in clinical settings only. “The flu is more than just a bad cold — it can knock you down for weeks. Getting vaccinated is the simplest way to protect yourself and your loved ones. With needle-free options like FluMist, staying protected has never been easier.” - Dr Sankeerth Reddy Expanding Beyond Aesthetics into Preventive Care Zest Clinic’s core services include aesthetic medicine, men’s and women’s health, and wellness and longevity programmes such as health screenings and selected vaccinations. The introduction of an intranasal flu vaccine extends this preventive care work, allowing patients who visit for aesthetic or wellness reasons to address broader health concerns in the same setting under medical supervision. How the Intranasal Flu Vaccine Works FluMist is delivered as a fine mist into the nostrils. Instead of an intramuscular injection, a small volume of spray exposes the nasal passages to weakened influenza viruses that help the body build immunity against circulating strains. By targeting the entry point of many respiratory infections, the vaccine stimulates both local and systemic immune responses. The local (nasal mucosa) protection is what makes it a game changer compared to the injectable form. Clinical Effectiveness and Patient Selection International data indicate that intranasal influenza vaccines can be at least as effective as traditional injectable vaccines in specific age groups and seasons, but they are not suitable for everyone. Individuals with certain chronic medical conditions, weakened immune systems or other contraindications may be better served by an inactivated injectable vaccine, in line with current recommendations. It has been approved for individuals between the age 2 years to 49 years. At Zest Clinic, every vaccination is preceded by a medical consultation to review the patient’s history and risk profile. The choice between FluMist and an injectable influenza vaccine is based on clinical considerations and patient preferences. “Influenza Immunisation is not just about protecting one person — it’s about protecting the whole family. When parents, children, and grandparents are vaccinated, we create a strong shield that helps prevent infections from spreading at home and in the community. A family that vaccinates together stay strong together.” - Dr Tiffany Yeo- Reddy Clinic-Administered Only in Singapore Unlike in some overseas settings where intranasal influenza vaccines may be used at home, FluMist in Singapore is currently approved for clinic use only. At Zest Clinic, the vaccine is administered by trained staff in a controlled environment, with brief post-vaccination observation so that any immediate side effects, such as mild nasal irritation, can be monitored. The vaccination is $60 Nett Price. About Zest Clinic Zest Clinic is located at Parkway Parade Medical Centre, 80 Marine Parade Road, Singapore. The clinic provides aesthetic medicine, men’s and women’s health services, and wellness and longevity programmes, including health screenings and vaccinations. Its team of doctors and staff aim to combine evidence-based medical care with a patient-centred approach that considers both appearance and long-term health. Media and RSVP Contact Zest Clinic 80 Marine Parade Road, #05-04/05 Parkway Parade Medical Centre Singapore 449269 Tel / WhatsApp: +65 9176 9378 Email: info@zest.clinic https://www.zest.clinic/ Dr. Tiffany Yeo-Reddy Zest Clinic +65 6995 0470 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A H3N2 subclade K. According to the World Health Organization, seasonal influenza causes approximately 3–5 million cases of severe illness annually, resulting in 290,000–650,000 respiratory fatalities. This year's flu vaccine is mismatched with subclade K (or "J.2.4.1"), which has limited natural immunity within communities. influenza A subtype H3N2 has historically been associated with higher rates of hospitalization and death, and preliminary data has already linked subclade K to countries like Japan and the United Kingdom experiencing earlier than usual flu seasons in 2025, following Australia reporting a record flu season. "We have received customer inquiries regarding the performance of the Logix Smart ABC test against this year's influenza strains," remarked Dwight Egan, CEO of Co-Dx. "Based on the results of this analysis, we are confident that the test retains comparable sensitivity as when it was first developed on our proprietary platform more than five years ago. This consistency underscores the stability of our technology and our commitment to expanding access to high-quality PCR testing solutions." In November 2020, the Logix Smart ABC test received CE-marking for the simultaneous detection of and differentiation of influenza A, influenza B, and SARS-CoV-2, the virus that causes COVID-19. The test's Co-Primers target a region on the MP gene of influenza A, whereas the mutations associated with subclade K occur in the HA region of the genome. The in silico analysis concluded that there is no concern that any emerging H3N2 strains would affect the test kit's sensitivity. The Logix Smart ABC test is intended for use by qualified and trained clinical laboratory personnel. In November 2025, the Company announced that it had initiated clinical performance testing for the Co-Dx PCR Flu A/B, COVID-19, RSV point-of-care upper-respiratory multiplex test**, which is intended to support a submission to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. Similar to the Logix Smart test, the flu A targets in this test are not expected to be affected by H3N2 subclade K. *This test is not approved or cleared by the U.S. Food and Drug Administration (FDA). It is for export only and is not for sale in the United States. **The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the expected performance and sensitivity of the Company's diagnostic tests, the impact of influenza virus mutations, ongoing and planned clinical testing, and potential regulatory submissions and approvals. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks and uncertainties include, but are not limited to, changes in viral genomics, regulatory review processes, clinical and analytical performance results, manufacturing and supply considerations, market conditions, and other risks described from time to time in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law. SOURCE Co-Diagnostics 21% more press release views with Request a Demo